Condition: Solid Tumor · Cancer · Sponsor: Singlomics Biopharmaceuticals Zhuhai Co., Ltd.
The goal of this clinical trial is to evaluate the safety and tolerability of DXP-106 in Chinese patients with advanced solid tumors. The main questions it aims to answer are: For Part I: 1. The safety and tolerability of DXP-106 monotherapy in patients with advanced solid tumors; 2. The dose-limiting toxicities (DLTs) and determine the maximum tolerated dose (MTD) and/or the recommended Phase II dose (RP2D); 3. The pharmacokinetics (PK) profile, the immunogenicity of DXP-106 following administration in patients with advanced solid tumors; 4. The preliminary efficacy of DXP-106 in patients with advanced solid tumors; 5. The pharmacodynamic (PD) profiles of DXP-106 following administration in patients with advanced solid tumors as exploratory objective; For Part2: 1. The safety and tolerability of DXP-106 in combination with standard of care chemotherapy in patients with advanced solid tumors; 2. The recommended dose of DXP-106 in combination with standard of care chemotherapy and/or potential responsive tumor types; 3. The efficacy of DXP-106 in combination with standard of care chemotherapy in patients with advanced solid tumors; 4. The PK profile and immunogenicity of DXP-106 in combination with standard of care chemotherapy in patients with advanced solid tumors; 5. The PD profiles of DXP-106 in combination with standard of care chemotherapy in patients with advanced solid tumors. The dose escalation is designed with five cohorts, including Cohort 1 (1.0 mg/kg), Cohor…
This description comes directly from the study's public registry record.
Mingli Guo ML Guo, Master · 86-010-80765087 · mingli.guo@singlomics.com
Huilian HL Zeng, Bachlor · China: 86-010-80765087 · huilian.zeng@singlomics.com
Always discuss trial participation with your own doctor first.
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang, China | Not Yet Recruiting |
| Zhongshan Hospital, Fudan University | Shanghai, Shanghai Municipality, China | Recruiting |
| Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University | Hangzhou, Zhejiang, China | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07532018